Five Japanese series evaluating EGFR gene mutations in non-small cell lung cancer (NSCLC) detected them in 0–5.8% of ILD patients vs. 24.3–47% of those without ILD [17,85,86,87,88]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.